Records: Certain bulk drug substances for use in compounding may present significant safety risks, WADA Prohibited List: S0 Non-Approved Substances, July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting Evidence timeline What changed, and when Sikiric and colleagues characterize BPC-157 as a 15-amino-acid fragment of a larger gastric-juice peptide
The opposite problem occurs with concentrated compounds like GHK-Cu at 50 mg
There have been postmarketing reports of renal impairment, acute kidney injury, and worsening of chronic renal failure, which sometimes has required hemodialysis, in patients treated with GLP-1 receptor agonists
Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made